Market Cap | 46.19M |
Revenue (ttm) | n/a |
Net Income (ttm) | -31.50M |
Shares Out | 88.82M |
EPS (ttm) | -0.40 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 188,210 |
Average Volume | 102,587 |
Open | 0.5600 |
Previous Close | 0.5600 |
Day's Range | 0.5200 - 0.5600 |
52-Week Range | 0.5200 - 2.0800 |
Beta | 1.51 |
RSI | 31.55 |
Earnings Date | May 7, 2025 |
About Oncolytics Biotech
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing... [Read more]
Financial Performance
Financial StatementsNews

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities
Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses New analyses confirm that pelareorep primes the TME to allow circulating tumor-inf...
Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2025 Results Conference Call May 14, 2025 4:30 PM ETCompany ParticipantsJon Patton - Director of Investor Relations...

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum
American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion Leader event on oncolytic imm...
Oncolytics Biotech Q1 2025 Earnings Preview
A Look at Oncolytics Biotech's Upcoming Earnings Report
Oncolytics Biotech (NASDAQ: ONCY) is set to give its latest quarterly earnings report on Wednesday, 2025-05-14. Here's what investors need to know before the announcement. Analysts estimate that Onco...

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , May 6, 2025 Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-sta...

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action
ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients Ongoing updates support potential of pelareorep combination therapies in one of the deadliest an...

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
SAN DIEGO and CALGARY, AB , April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, has entered ...

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
SAN DIEGO and CALGARY, AB , April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, was discusse...
Oncolytics Biotech: Continuing To Justify The Negativity
Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript
Oncolytics Biotech GAAP EPS of -$0.41 misses by $0.10

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024
BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancreatic and anal carcinoma support con...

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024
BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancreatic and anal carcinoma support con...
Oncolytics Biotech Q4 2024 Earnings Preview

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Feb. 25, 2025 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a l...

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025
Regulatory progress in pancreatic cancer and recent clinical data presentations in two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, highlight pelareorep's potential...

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, demonstrate the potential of pelareorep across very different tumor typ...
Oncolytics Biotech receives Nasdaq non-compliance notice

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
SAN DIEGO and CALGARY, AB , Feb. 14, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announc...

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence
Search for Chief Executive Officer to commence immediately SAN DIEGO and CALGARY, AB , Feb. 7, 2025 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage comp...

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence
Search for Chief Executive Officer to commence immediately SAN DIEGO and CALGARY, AB , Feb. 7, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage compa...

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium
Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patients Pelareorep-based therapy demonstrates strong safety profile with new chem...

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium
Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patients Pelareorep-based therapy demonstrates strong safety profile with new chem...

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data
New pancreatic cancer cohort moves forward with full enrollment of 30 patients in Stage 1 SAN DIEGO and CALGARY, AB , Jan. 15, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), ...